Search

Your search keyword '"Kristensen, Lasse S"' showing total 148 results
Start Over Author "Kristensen, Lasse S" Publication Year Range Last 50 years
148 results on '"Kristensen, Lasse S"'

4. Best practice standards for circular RNA research

Author

Nielsen, Anne F., Bindereif, Albrecht, Bozzoni, Irene, Hanan, Mor, Hansen, Thomas B., Irimia, Manuel, Kadener, Sebastian, Kristensen, Lasse S., Legnini, Ivano, Morlando, Mariangela, Jarlstad Olesen, Morten T., Pasterkamp, R. Jeroen, Preibisch, Stephan, Rajewsky, Nikolaus, Suenkel, Christin, and Kjems, Jørgen

Published
2022
Full Text
View/download PDF

8. TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS‐CoV‐2 infection

Author

van der Sluis, Renée M, Cham, Lamin B, Gris‐Oliver, Albert, Gammelgaard, Kristine R, Pedersen, Jesper G, Idorn, Manja, Ahmadov, Ulvi, Hernandez, Sabina Sanches, Cémalovic, Ena, Godsk, Stine H, Thyrsted, Jacob, Gunst, Jesper D, Nielsen, Silke D, Jørgensen, Janni J, Bjerg, Tobias Wang, Laustsen, Anders, Reinert, Line S, Olagnier, David, Bak, Rasmus O, Kjolby, Mads, Holm, Christian K, Tolstrup, Martin, Paludan, Søren R, Kristensen, Lasse S, Søgaard, Ole S, and Jakobsen, Martin R

Published
2022
Full Text
View/download PDF

11. Supplementary Fig. 3 from Spatial Profiling of Circular RNAs in Cancer Reveals High Expression in Muscle and Stromal Cells

Author

García-Rodríguez, Juan L., primary, Korsgaard, Ulrik, primary, Ahmadov, Ulvi, primary, Jarlstad Olesen, Morten T., primary, Dietrich, Kim-Gwendolyn, primary, Hansen, Emma B., primary, Vissing, Stine M., primary, Ulhøi, Benedichte P., primary, Dyrskjøt, Lars, primary, Sørensen, Karina D., primary, Kjems, Jørgen, primary, Hager, Henrik, primary, and Kristensen, Lasse S., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Fig. 10 from Spatial Profiling of Circular RNAs in Cancer Reveals High Expression in Muscle and Stromal Cells

Author

García-Rodríguez, Juan L., primary, Korsgaard, Ulrik, primary, Ahmadov, Ulvi, primary, Jarlstad Olesen, Morten T., primary, Dietrich, Kim-Gwendolyn, primary, Hansen, Emma B., primary, Vissing, Stine M., primary, Ulhøi, Benedichte P., primary, Dyrskjøt, Lars, primary, Sørensen, Karina D., primary, Kjems, Jørgen, primary, Hager, Henrik, primary, and Kristensen, Lasse S., primary

Published
2023
Full Text
View/download PDF

13. Data from Spatial Profiling of Circular RNAs in Cancer Reveals High Expression in Muscle and Stromal Cells

Author

García-Rodríguez, Juan L., primary, Korsgaard, Ulrik, primary, Ahmadov, Ulvi, primary, Jarlstad Olesen, Morten T., primary, Dietrich, Kim-Gwendolyn, primary, Hansen, Emma B., primary, Vissing, Stine M., primary, Ulhøi, Benedichte P., primary, Dyrskjøt, Lars, primary, Sørensen, Karina D., primary, Kjems, Jørgen, primary, Hager, Henrik, primary, and Kristensen, Lasse S., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Fig. 9 from Spatial Profiling of Circular RNAs in Cancer Reveals High Expression in Muscle and Stromal Cells

Author

García-Rodríguez, Juan L., primary, Korsgaard, Ulrik, primary, Ahmadov, Ulvi, primary, Jarlstad Olesen, Morten T., primary, Dietrich, Kim-Gwendolyn, primary, Hansen, Emma B., primary, Vissing, Stine M., primary, Ulhøi, Benedichte P., primary, Dyrskjøt, Lars, primary, Sørensen, Karina D., primary, Kjems, Jørgen, primary, Hager, Henrik, primary, and Kristensen, Lasse S., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Fig. 7 from Spatial Profiling of Circular RNAs in Cancer Reveals High Expression in Muscle and Stromal Cells

Author

García-Rodríguez, Juan L., primary, Korsgaard, Ulrik, primary, Ahmadov, Ulvi, primary, Jarlstad Olesen, Morten T., primary, Dietrich, Kim-Gwendolyn, primary, Hansen, Emma B., primary, Vissing, Stine M., primary, Ulhøi, Benedichte P., primary, Dyrskjøt, Lars, primary, Sørensen, Karina D., primary, Kjems, Jørgen, primary, Hager, Henrik, primary, and Kristensen, Lasse S., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Table 1 from Spatial Profiling of Circular RNAs in Cancer Reveals High Expression in Muscle and Stromal Cells

Author

García-Rodríguez, Juan L., primary, Korsgaard, Ulrik, primary, Ahmadov, Ulvi, primary, Jarlstad Olesen, Morten T., primary, Dietrich, Kim-Gwendolyn, primary, Hansen, Emma B., primary, Vissing, Stine M., primary, Ulhøi, Benedichte P., primary, Dyrskjøt, Lars, primary, Sørensen, Karina D., primary, Kjems, Jørgen, primary, Hager, Henrik, primary, and Kristensen, Lasse S., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Fig. 2 from Spatial Profiling of Circular RNAs in Cancer Reveals High Expression in Muscle and Stromal Cells

Author

García-Rodríguez, Juan L., primary, Korsgaard, Ulrik, primary, Ahmadov, Ulvi, primary, Jarlstad Olesen, Morten T., primary, Dietrich, Kim-Gwendolyn, primary, Hansen, Emma B., primary, Vissing, Stine M., primary, Ulhøi, Benedichte P., primary, Dyrskjøt, Lars, primary, Sørensen, Karina D., primary, Kjems, Jørgen, primary, Hager, Henrik, primary, and Kristensen, Lasse S., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Table 2 from Spatial Profiling of Circular RNAs in Cancer Reveals High Expression in Muscle and Stromal Cells

Author

García-Rodríguez, Juan L., primary, Korsgaard, Ulrik, primary, Ahmadov, Ulvi, primary, Jarlstad Olesen, Morten T., primary, Dietrich, Kim-Gwendolyn, primary, Hansen, Emma B., primary, Vissing, Stine M., primary, Ulhøi, Benedichte P., primary, Dyrskjøt, Lars, primary, Sørensen, Karina D., primary, Kjems, Jørgen, primary, Hager, Henrik, primary, and Kristensen, Lasse S., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Fig. 5 from Spatial Profiling of Circular RNAs in Cancer Reveals High Expression in Muscle and Stromal Cells

Author

García-Rodríguez, Juan L., primary, Korsgaard, Ulrik, primary, Ahmadov, Ulvi, primary, Jarlstad Olesen, Morten T., primary, Dietrich, Kim-Gwendolyn, primary, Hansen, Emma B., primary, Vissing, Stine M., primary, Ulhøi, Benedichte P., primary, Dyrskjøt, Lars, primary, Sørensen, Karina D., primary, Kjems, Jørgen, primary, Hager, Henrik, primary, and Kristensen, Lasse S., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Fig. 6 from Spatial Profiling of Circular RNAs in Cancer Reveals High Expression in Muscle and Stromal Cells

Author

García-Rodríguez, Juan L., primary, Korsgaard, Ulrik, primary, Ahmadov, Ulvi, primary, Jarlstad Olesen, Morten T., primary, Dietrich, Kim-Gwendolyn, primary, Hansen, Emma B., primary, Vissing, Stine M., primary, Ulhøi, Benedichte P., primary, Dyrskjøt, Lars, primary, Sørensen, Karina D., primary, Kjems, Jørgen, primary, Hager, Henrik, primary, and Kristensen, Lasse S., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Fig. 8 from Spatial Profiling of Circular RNAs in Cancer Reveals High Expression in Muscle and Stromal Cells

Author

García-Rodríguez, Juan L., primary, Korsgaard, Ulrik, primary, Ahmadov, Ulvi, primary, Jarlstad Olesen, Morten T., primary, Dietrich, Kim-Gwendolyn, primary, Hansen, Emma B., primary, Vissing, Stine M., primary, Ulhøi, Benedichte P., primary, Dyrskjøt, Lars, primary, Sørensen, Karina D., primary, Kjems, Jørgen, primary, Hager, Henrik, primary, and Kristensen, Lasse S., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Fig. 4 from Spatial Profiling of Circular RNAs in Cancer Reveals High Expression in Muscle and Stromal Cells

Author

García-Rodríguez, Juan L., primary, Korsgaard, Ulrik, primary, Ahmadov, Ulvi, primary, Jarlstad Olesen, Morten T., primary, Dietrich, Kim-Gwendolyn, primary, Hansen, Emma B., primary, Vissing, Stine M., primary, Ulhøi, Benedichte P., primary, Dyrskjøt, Lars, primary, Sørensen, Karina D., primary, Kjems, Jørgen, primary, Hager, Henrik, primary, and Kristensen, Lasse S., primary

Published
2023
Full Text
View/download PDF

24. Spatial Profiling of Circular RNAs in Cancer Reveals High Expression in Muscle and Stromal Cells

Author

García-Rodríguez, Juan L., primary, Korsgaard, Ulrik, additional, Ahmadov, Ulvi, additional, Jarlstad Olesen, Morten T., additional, Dietrich, Kim-Gwendolyn, additional, Hansen, Emma B., additional, Vissing, Stine M., additional, Ulhøi, Benedichte P., additional, Dyrskjøt, Lars, additional, Sørensen, Karina D., additional, Kjems, Jørgen, additional, Hager, Henrik, additional, and Kristensen, Lasse S., additional

Published
2023
Full Text
View/download PDF

27. Best practice standards for circular RNA research

Author

Translational Neuroscience, Brain, Regenerative Medicine and Stem Cells, Nielsen, Anne F., Bindereif, Albrecht, Bozzoni, Irene, Hanan, Mor, Hansen, Thomas B., Irimia, Manuel, Kadener, Sebastian, Kristensen, Lasse S., Legnini, Ivano, Morlando, Mariangela, Jarlstad Olesen, Morten T., Pasterkamp, R. Jeroen, Preibisch, Stephan, Rajewsky, Nikolaus, Suenkel, Christin, Kjems, Jørgen, Translational Neuroscience, Brain, Regenerative Medicine and Stem Cells, Nielsen, Anne F., Bindereif, Albrecht, Bozzoni, Irene, Hanan, Mor, Hansen, Thomas B., Irimia, Manuel, Kadener, Sebastian, Kristensen, Lasse S., Legnini, Ivano, Morlando, Mariangela, Jarlstad Olesen, Morten T., Pasterkamp, R. Jeroen, Preibisch, Stephan, Rajewsky, Nikolaus, Suenkel, Christin, and Kjems, Jørgen

Published
2022

28. TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS‐CoV‐2 infection

Author

Sluis, Renée M, primary, Cham, Lamin B, additional, Gris‐Oliver, Albert, additional, Gammelgaard, Kristine R, additional, Pedersen, Jesper G, additional, Idorn, Manja, additional, Ahmadov, Ulvi, additional, Hernandez, Sabina Sanches, additional, Cémalovic, Ena, additional, Godsk, Stine H, additional, Thyrsted, Jacob, additional, Gunst, Jesper D, additional, Nielsen, Silke D, additional, Jørgensen, Janni J, additional, Bjerg, Tobias Wang, additional, Laustsen, Anders, additional, Reinert, Line S, additional, Olagnier, David, additional, Bak, Rasmus O, additional, Kjolby, Mads, additional, Holm, Christian K, additional, Tolstrup, Martin, additional, Paludan, Søren R, additional, Kristensen, Lasse S, additional, Søgaard, Ole S, additional, and Jakobsen, Martin R, additional

Published
2022
Full Text
View/download PDF

31. Distinct SARS-CoV-2 sensing pathways in pDCs driving TLR7-antiviral vs. TLR2-immunopathological responses in COVID-19

Author

van der Sluis, Renee M, primary, Cham, Lamin B, additional, Oliver, Alberg Gris, additional, Gammelgaard, Kristine Raaby, additional, Pedersen, Jesper Geert, additional, Idorn, Manja, additional, Ahmodov, Ulvi, additional, Hernandez, Sabina S, additional, Cemalovic, Ena, additional, Godsk, Stine H, additional, Thyrsted, Jakob, additional, Gunst, Jesper D, additional, Nielsen, Silke D, additional, Jorgensen, Janni j, additional, Bjerg, Tobias W, additional, Laustsen, Anders, additional, Reinert, Line, additional, Olagnier, David, additional, Bak, Rasmus O., additional, Kjolby, Mads, additional, Holm, Christian Kanstrup, additional, Tolstrup, Martin, additional, Paludan, Soren R., additional, Kristensen, lasse S, additional, Sogaard, Ole S, additional, and Jakobsen, Martin R, additional

Published
2021
Full Text
View/download PDF

33. Predicting response to epigenetic therapy

Author

Treppendahl, Marianne B., Kristensen, Lasse S., and Gronbaek, Kirsten

Subjects
Cancer patients -- Health aspects -- Research, Chemotherapy -- Health aspects, Cancer -- Care and treatment -- Patient outcomes -- Research -- Chemotherapy, Health care industry
Abstract

Drugs targeting the epigenome are new promising cancer treatment modalities; however, not all patients receive the same benefit from these drugs. In contrast to conventional chemotherapy, responses may take several months after the initiation of treatment to occur. Accordingly, identification of good pretreatment predictors of response is of great value. Many clinical parameters and molecular targets have been tested in preclinical and clinical studies with varying results, leaving room for optimization. Here we provide an overview of markers that may predict the efficacy of FDA- and EMA-approved epigenetic drugs., Introduction Traditionally, cancer patients have been offered the type of chemotherapy that has shown efficacy in the largest proportion of individuals suffering from that particular type of cancer. However, given [...]

Published
2014
Full Text
View/download PDF

35. Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials

Author

Dahl, Mette, primary, Husby, Simon, additional, Eskelund, Christian W., additional, Besenbacher, Søren, additional, Fjelstrup, Søren, additional, Côme, Christophe, additional, Ek, Sara, additional, Kolstad, Arne, additional, Räty, Riikka, additional, Jerkeman, Mats, additional, Geisler, Christian H., additional, Kjems, Jørgen, additional, Kristensen, Lasse S., additional, and Grønbæk, Kirsten, additional

Published
2021
Full Text
View/download PDF

36. Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma:a study of younger patients from the MCL2 and MCL3 clinical trials

Author

Dahl, Mette, Husby, Simon, Eskelund, Christian W, Besenbacher, Søren, Fjelstrup, Søren, Côme, Christophe, Ek, Sara, Kolstad, Arne, Räty, Riikka, Jerkeman, Mats, Geisler, Christian H, Kjems, Jørgen, Kristensen, Lasse S, Grønbæk, Kirsten, Dahl, Mette, Husby, Simon, Eskelund, Christian W, Besenbacher, Søren, Fjelstrup, Søren, Côme, Christophe, Ek, Sara, Kolstad, Arne, Räty, Riikka, Jerkeman, Mats, Geisler, Christian H, Kjems, Jørgen, Kristensen, Lasse S, and Grønbæk, Kirsten

Abstract

Mantle cell lymphoma (MCL) is characterized by marked differences in outcome, emphasizing the need for strong prognostic biomarkers. Here, we explore expression patterns and prognostic relevance of circular RNAs (circRNAs), a group of endogenous non-coding RNA molecules, in MCL. We profiled the circRNA expression landscape using RNA-sequencing and explored the prognostic potential of 40 abundant circRNAs in samples from the Nordic MCL2 and MCL3 clinical trials, using NanoString nCounter Technology. We report a circRNA-based signature (circSCORE) developed in the training cohort MCL2 that is highly predictive of time to progression (TTP) and lymphoma-specific survival (LSS). The dismal outcome observed in the large proportion of patients assigned to the circSCORE high-risk group was confirmed in the independent validation cohort MCL3, both in terms of TTP (HR 3.0; P = 0.0004) and LSS (HR 3.6; P = 0.001). In Cox multiple regression analysis incorporating MIPI, Ki67 index, blastoid morphology and presence of TP53 mutations, circSCORE retained prognostic significance for TTP (HR 3.2; P = 0.01) and LSS (HR 4.6; P = 0.01). In conclusion, circRNAs are promising prognostic biomarkers in MCL and circSCORE improves identification of high-risk disease among younger patients treated with cytarabine-containing chemoimmunotherapy and autologous stem cell transplant.

Published
2021

38. Impact of U2AF1mutations on circular RNA expression in myelodysplastic neoplasms

Author

Wedge, Eileen, Ahmadov, Ulvi, Hansen, Thomas B., Gao, Zongliang, Tulstrup, Morten, Côme, Christophe, Nonavinkere Srivatsan, Sridhar, Ahmed, Tanzir, Jespersen, Jakob S., Schlotmann, Balthasar C., Schöllkopf, Claudia, Raaschou-Jensen, Klas, Ødum, Niels, Kjems, Jørgen, Bak, Rasmus O., Walter, Matthew J., Grønbæk, Kirsten, and Kristensen, Lasse S.

Abstract

Mutations in U2AF1are relatively common in myelodysplastic neoplasms (MDS) and are associated with an inferior prognosis, but the molecular mechanisms underlying this are not fully elucidated. Circular RNAs (circRNAs) have been implicated in cancer, but it is unknown how mutations in splicing factors may impact on circRNA biogenesis. Here, we used RNA-sequencing to investigate the effects of U2AF1mutations on circRNA expression in K562 cells with a doxycycline-inducible U2AF1S34mutation, in a mouse model with a doxycycline-inducible U2AF1S34mutation, and in FACS-sorted CD34+ bone marrow cells from MDS patients with either U2AF1S34or U2AF1Q157mutations. In all contexts, we found an increase in global circRNA levels in the U2AF1-mutated setting, which was independent of expression changes in the cognate linear host genes. In patients, the U2AF1S34and U2AF1Q157mutations were both associated with an overall increased expression of circRNAs. circRNAs generated by a non-Alu-mediated mechanism generally showed the largest increase in expression levels. Several well-described cancer-associated circRNAs, including circZNF609 and circCSNK1G3, were upregulated in MDS patients with U2AF1mutations compared to U2AF1-wildtype MDS controls. In conclusion, high circRNA expression is observed in association with U2AF1mutations in three biological systems, presenting an interesting possibility for biomarker and therapeutic investigation.

Published
2023
Full Text
View/download PDF

46. Characterization of circular RNA transcriptomes in psoriasis and atopic dermatitis reveals disease‐specific expression profiles.

Author

Moldovan, Liviu I., Tsoi, Lam C., Ranjitha, Uppala, Hager, Henrik, Weidinger, Stephen, Gudjonsson, Johann E., Kjems, Jørgen, and Kristensen, Lasse S.

Subjects
CIRCULAR RNA, ATOPIC dermatitis, TRANSCRIPTOMES, PSORIASIS, NON-coding RNA, PSORIATIC arthritis
Abstract

Atopic dermatitis (AD) and psoriasis are two common chronic inflammatory skin diseases that are associated with various comorbidities. Circular RNA (circRNA) constitutes a major class of non‐coding RNAs that have been implicated in many human diseases, although their potential involvement in inflammatory skin diseases remains elusive. Here, we compare and contrast the circRNA expression landscapes in paired lesional and non‐lesional skin from psoriasis and AD patients relative to skin from unaffected individuals using high‐depth RNA‐seq data. CircRNAs and their cognate linear transcripts were quantified using the circRNA detection algorithm, CIRI2, and in situ hybridization and Sanger sequencing was used for validation purposes. We identified 39,286 circRNAs among all samples and found that psoriasis and AD lesional skin could be distinguished from non‐lesional and healthy skin based on circRNA expression landscapes. In general, circRNAs were less abundant in lesional relative to non‐lesional and healthy skin. Differential expression analyses revealed many significantly downregulated circRNAs, mainly in psoriasis lesional skin, and a strong correlation between psoriasis and AD‐related circRNA expression changes was observed. Two individual circRNAs, ciRS‐7 (also known as CDR1as) and circZRANB1, were specifically dysregulated in psoriasis and show promise as biomarkers for discriminating AD from psoriasis. In conclusion, the circRNA transcriptomes of psoriasis and AD share expression features, including a global downregulation relative to healthy skin, but this is most pronounced in psoriasis, and only psoriasis is characterized by several circRNAs being dysregulated independently of their cognate linear transcripts. Finally, specific circRNAs could potentially be used to distinguish AD from psoriasis. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

48. Quality assessment of DNA derived from up to 30 years old formalin fixed paraffin embedded (FFPE) tissue for PCR-based methylation analysis using SMART-MSP and MS-HRM

Author

Hager Henrik, Wiuf Carsten, Thestrup Britta B, Wojdacz Tomasz K, Kristensen Lasse S, and Hansen Lise

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background The High Resolution Melting (HRM) technology has recently been introduced as a rapid and robust analysis tool for the detection of DNA methylation. The methylation status of multiple tumor suppressor genes may serve as biomarkers for early cancer diagnostics, for prediction of prognosis and for prediction of response to treatment. Therefore, it is important that methodologies for detection of DNA methylation continue to evolve. Sensitive Melting Analysis after Real Time - Methylation Specific PCR (SMART-MSP) and Methylation Sensitive - High Resolution Melting (MS-HRM) are two methods for single locus DNA methylation detection based on HRM. Methods Here, we have assessed the quality of DNA extracted from up to 30 years old Formalin Fixed Paraffin Embedded (FFPE) tissue for DNA methylation analysis using SMART-MSP and MS-HRM. The quality assessment was performed on DNA extracted from 54 Non-Small Cell Lung Cancer (NSCLC) samples derived from FFPE tissue, collected over 30 years and grouped into five years intervals. For each sample, the methylation levels of the CDKN2A (p16) and RARB promoters were estimated using SMART-MSP and MS-HRM assays designed to assess the methylation status of the same CpG positions. This allowed for a direct comparison of the methylation levels estimated by the two methods for each sample. Results CDKN2A promoter methylation levels were successfully determined by SMART-MSP and MS-HRM in all 54 samples. Identical methylation estimates were obtained by the two methods in 46 of the samples. The methylation levels of the RARB promoter were successfully determined by SMART-MSP in all samples. When using MS-HRM to assess RARB methylation five samples failed to amplify and 15 samples showed a melting profile characteristic for heterogeneous methylation. Twenty-seven of the remaining 34 samples, for which the methylation level could be estimated, gave the same result as observed when using SMART-MSP. Conclusion MS-HRM and SMART-MSP can be successfully used for single locus methylation studies using DNA derived from up to 30 years old FFPE tissue. Furthermore, it can be expected that MS-HRM and SMART-MSP will provide similar methylation estimates when assays are designed to analyze the same CpG positions.

Published
2009
Full Text
View/download PDF

50. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma

Author

Kristensen, Lasse S, Michaelsen, Signe R, Dyrbye, Henrik, Aslan, Derya, Grunnet, Kirsten, Christensen, Ib J, Poulsen, Hans S, Grønbæk, Kirsten, Broholm, Helle, Kristensen, Lasse S, Michaelsen, Signe R, Dyrbye, Henrik, Aslan, Derya, Grunnet, Kirsten, Christensen, Ib J, Poulsen, Hans S, Grønbæk, Kirsten, and Broholm, Helle

Abstract

Methylation of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene is a predictive and prognostic marker in newly diagnosed glioblastoma patients treated with temozolomide but how MGMT methylation should be assessed to ensure optimal detection accuracy is debated. We developed a novel quantitative methylation-specific PCR (qMSP) MGMT assay capable of providing allelic methylation data and analyzed 151 glioblastomas from patients receiving standard of care treatment (Stupp protocol). The samples were also analyzed by immunohistochemistry (IHC), standard bisulfite pyrosequencing, and genotyped for the rs1690252 MGMT promoter single nucleotide polymorphism. Monoallelic methylation was observed more frequently than biallelic methylation, and some cases with monoallelic methylation expressed the MGMT protein whereas others did not. The presence of MGMT methylation was associated with better overall survival (p = 0.006; qMSP and p = 0.002; standard pyrosequencing), and the presence of the protein was associated with worse overall survival (p = 0.009). Combined analyses of qMSP and standard pyrosequencing or IHC identified additional patients who benefited from temozolomide treatment. Finally, low methylation levels were also associated with better overall survival (p = 0.061; qMSP and p = 0.02; standard pyrosequencing). These data support the use of both MGMT methylation and MGMT IHC but not allelic methylation data as prognostic markers in patients with temozolomide-treated glioblastoma.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results